醋酸格拉替雷特异性人CD8(+) T细胞：醋酸格拉替雷治疗可降低多发性硬化症中增加的白细胞介素-4生成。
Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
作者信息
Dressel Alexander, Vogelgesang Antje, Brinkmeier Heinrich, Mäder Michael, Weber Frank
机构信息
Department of Neurology, Ernst Moritz Arndt University Greifswald, Sauerbruchstr., 17489 Greifswald, Germany.
出版信息
J Neuroimmunol. 2006 Dec;181(1-2):133-40. doi: 10.1016/j.jneuroim.2006.07.014. Epub 2006 Nov 7.
Glatiramer acetate (GA) is an approved drug for therapy of relapsing remitting MS that acts as a T cell antigen. Here, we report the cloning of HLA restricted, GA-specific human CD8(+) T cells. In addition, we analyzed the cytokine profile of GA-reactive CD8(+) T cell lines. Unexpectedly, IL-4 was increased in untreated MS patients as compared to healthy individuals (p<0.001). In GA-treated patients, however, IL-4 (p<0.001), IL-10 (p<0.001) and TNF-alpha (p<0.001) were decreased. Thus, while GA is known to induce a TH2 bias in CD4(+) T cells, we detected a distinct pattern in GA-reactive CD8(+) T cells.
醋酸格拉替雷（GA）是一种已获批准用于治疗复发缓解型多发性硬化症的药物，它作为一种T细胞抗原发挥作用。在此，我们报告了HLA限制的、GA特异性人类CD8(+) T细胞的克隆。此外，我们分析了GA反应性CD8(+) T细胞系的细胞因子谱。出乎意料的是，与健康个体相比，未经治疗的多发性硬化症患者体内的IL-4有所增加（p<0.001）。然而，在接受GA治疗的患者中，IL-4（p<0.001）、IL-10（p<0.001）和TNF-α（p<0.001）均有所下降。因此，虽然已知GA会在CD4(+) T细胞中诱导TH2偏向，但我们在GA反应性CD8(+) T细胞中检测到了一种不同的模式。
Zotero 插件